Magnesium Carbonate
| Evidence Level: L4 | Predicted Indications: 10 |
Table of Contents
- Magnesium Carbonate
- Magnesium Carbonate: From Peptic Ulcer Disease and Dyspepsia to Active Peptic Ulcer Disease
Magnesium Carbonate: From Peptic Ulcer Disease and Dyspepsia to Active Peptic Ulcer Disease
One-Sentence Summary
Magnesium carbonate is an antacid originally used for acid-related stomach conditions such as peptic ulcer disease, gastroesophageal reflux disease and dyspepsia. The TxGNN model predicts it may be effective for active peptic ulcer disease, but this overlaps with its existing use, and the support is limited to 0 clinical trials and 1 laboratory-based publication.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Peptic ulcer disease, gastroesophageal reflux disease, esophagitis, constipation, dyspepsia (the Singapore licence has no approved indication text on file) |
| Predicted New Indication | Active peptic ulcer disease |
| TxGNN Prediction Score | 99.96% |
| Evidence Level | L4 |
| Singapore Market Status | ✓ Marketed |
| Number of Registrations | 1 |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Detailed mechanism of action data is not currently available. Based on known information, magnesium carbonate is an antacid that neutralises gastric hydrochloric acid. This is a plausible way to relieve symptoms of acid-related ulcer disease.
Active peptic ulcer disease is closely related to the drug's original indication of peptic ulcer disease, so this is not a true repurposing candidate. The prediction mostly restates a use the drug already has. The only literature retrieved is a laboratory study of the acid-neutralising capacity of marketed antacids, which is indirect evidence with no patient outcome data.
Other predicted indications in the data follow the same pattern. Gastric ulcer, duodenal ulcer and stomach disease overlap with the labelled uses. Gastrojejunal ulcer, gastroduodenitis and duodenogastric reflux are mechanistically plausible but rest only on laboratory or small mucosal-protection studies. Peptic ulcer perforation, gastroparesis and duodenal obstruction have no clear mechanistic rationale for an antacid and no supporting studies.
Clinical Trial Evidence
Currently no related clinical trials registered.
Literature Evidence
| PMID | Year | Type | Journal | Key Findings |
|---|---|---|---|---|
| 35720246 | 2022 | In vitro / product quality study | Medicine and Pharmacy Reports | Evaluated the acid-neutralising capacity and other properties of antacids marketed in Morocco |
Singapore Market Information
| Authorization Number | Product Name | Dosage Form | Approved Indication |
|---|---|---|---|
| SIN03440P | INON GRANULES (SATO Pharmaceutical Co Ltd) | Granule | Not stated |
Safety Considerations
- Contraindications (from a knowledge graph, not product label text): The knowledge graph links the drug to a number of conditions, including:
- Kidney disease and nephrocalcinosis
- Liver disease, liver failure and hepatic encephalopathy
- Hypercalcaemia and hyperparathyroidism
- Porphyria
- Blood disorders (anaemia, neutropenia, agranulocytosis, thrombocytopenia)
- Sleep apnoea syndromes
- Diarrhoeal disease
These associations have not been checked against the Singapore package insert and should be verified before use.
- Drug Interactions: The compiled data lists 100 interactions, of which 20 are shown here.
- Major: Dolutegravir.
- Moderate: Acalabrutinib, doxycycline, alendronic acid, risedronic acid, cholecalciferol, amphetamine, acetylsalicylic acid, atazanavir, atropine, azithromycin, baloxavir marboxil, benzphetamine.
- Minor: Acebutolol, famotidine, ranitidine, alprazolam, atenolol, axitinib, benazepril.
Antacids containing magnesium commonly reduce absorption of other drugs by binding them, so dose timing matters.
Please refer to the package insert for warnings and formal contraindications.
Conclusion and Next Steps
Decision: Hold
Rationale: The top prediction largely overlaps with the drug's existing use in peptic ulcer disease. The only supporting evidence is a laboratory study with no clinical outcomes. There are no registered trials, so this is not a strong new repurposing opportunity at this stage.
To proceed, the following is needed:
- The Singapore package insert, including its warnings, contraindications and approved indication text. This is a blocking gap for safety screening.
- Mechanism of action data, such as from DrugBank.
- Clinical studies of magnesium carbonate itself in peptic ulcer or related conditions such as gastrojejunal ulcer or duodenogastric reflux.
- A review of the interaction profile, especially the major interaction with dolutegravir, and guidance on dose spacing.
- Confirmation of which predicted indications are genuinely new rather than part of the existing labelled use.
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.